AZN :FDA Oks Wainua For Treatment Of Polyneuropathy Of Hereditary Transthyretin-Mediated Amyloidosis

(RTTNews) - The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals Inc. (IONS) and AstraZeneca's (AZN.L, AZN) Wainua or eplontersen for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR- https://www.nasdaq.com/articles/azn-:fda-oks-wainua-for-treatment-of-polyneuropathy-of-hereditary-transthyretin-mediated